Denzil Bernard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1210960/publications.pdf

Version: 2024-02-01

43 papers	3,408 citations	236925 25 h-index	302126 39 g-index
44 all docs	44 docs citations	44 times ranked	4907 citing authors

#	Article	IF	Citations
1	Follicular Lymphomaâ€“associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. Clinical Cancer Research, 2021, 27, 2301-2313.	7.0	16
2	Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. Nature Communications, 2021, 12, 2621.	12.8	15
3	Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. ACS Medicinal Chemistry Letters, 2020, 11, 1348-1352.	2.8	9
4	Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 6015-6034.	6.4	20
5	Follicular lymphomaâ€“associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR. Journal of Clinical Investigation, 2019, 129, 1626-1640.	8.2	23
6	High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2018, 61, 1934-1950.	6.4	46
7	Design of the Firstâ€inâ€Class, Highly Potent Irreversible Inhibitor Targeting the Meninâ€MLL Proteinâ€“Protein Interaction. Angewandte Chemie - International Edition, 2018, 57, 1601-1605.	13.8	49
8	Design of the Firstâ€inâ€Class, Highly Potent Irreversible Inhibitor Targeting the Meninâ€MLL Proteinâ€“Protein Interaction. Angewandte Chemie, 2018, 130, 1617-1621.	2.0	1
9	Targeting the MDM2â€“p53 Proteinâ€“Protein Interaction for New Cancer Therapy: Progress and Challenges. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026245.	6.2	217
10	Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)â€“Mixed Lineage Leukemia (MLL) Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2017, 60, 4818-4839.	6.4	72
11	Discovery of 4-((3â€²R,4â€²S,5â€²R)-6â€³-Chloro-4â€²-(3-chloro-2-fluorophenyl)-1â€²-ethyl-2â€³-oxodispiro[cyclohexane-1,2â€ Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. Journal of Medicinal Chemistry, 2017, 60, 2819-2839.	6.4	143
12	A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation. Nature Communications, 2017, 8, 1150.	12.8	71
13	Functional Analyses of BTK Mutations in Follicular Lymphoma. Blood, 2017, 130, 647-647.	1.4	0
14	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. Clinical Cancer Research, 2016, 22, 5383-5393.	7.0	36
15	Functional Analyses of V-Atpase Mutations in Follicular Lymphoma. Blood, 2016, 128, 1762-1762.	1.4	0
16	Activating STAT6 mutations in follicular lymphoma. Blood, 2015, 125, 668-679.	1.4	117
17	Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 proteinâ€“protein interaction as inhibitors of the MLL1 methyltransferase activity. Chinese Chemical Letters, 2015, 26, 455-458.	9.0	4
18	Small-Molecule Inhibitors of the MDM2â€“p53 Proteinâ€“Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment. Journal of Medicinal Chemistry, 2015, 58, 1038-1052.	6.4	390

#	Article	IF	Citations
19	Case Study: Discovery of Inhibitors of the MDM2â€“p53 Protein-Protein Interaction. Methods in Molecular Biology, 2015, 1278, 567-585.	0.9	4
20	Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways. Blood, 2015, 126, 112-112.	1.4	1
21	Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles. Journal of Medicinal Chemistry, 2014, 57, 10486-10498.	6.4	57
22	SAR405838: An Optimized Inhibitor of MDM2â€“p53 Interaction That Induces Complete and Durable Tumor Regression. Cancer Research, 2014, 74, 5855-5865.	0.9	261
23	Structure-Based Design of High-Affinity Macrocyclic Peptidomimetics to Block the Menin-Mixed Lineage Leukemia 1 (MLL1) Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2013, 56, 1113-1123.	6.4	78
24	High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Proteinâ€“Protein Interaction. Journal of the American Chemical Society, 2013, 135, 669-682.	13.7	157
25	Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors. Journal of the American Chemical Society, 2013, 135, 7223-7234.	13.7	200
26	A Potent Small-Molecule Inhibitor of the MDM2â€“p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. Journal of Medicinal Chemistry, 2013, 56, 5553-5561.	6.4	229
27	Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics. Topics in Medicinal Chemistry, 2012, , 57-79.	0.8	60
28	AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development. Journal of Medicinal Chemistry, 2012, 55, 4934-4935.	6.4	32
29	Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia.. Cancer Research, 2011, 71, LB-204-LB-204.	0.9	3
30	Case Study: Inhibitors of the MDM2â€p53 Proteinâ€“Protein Interaction. , 2010, , 273-293.		0
31	Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions. Journal of Biological Chemistry, 2010, 285, 21023-21036.	3.4	33
32	Analysis of the Binding of Mixed Lineage Leukemia 1 (MLL1) and Histone 3 Peptides to WD Repeat Domain 5 (WDR5) for the Design of Inhibitors of the MLL1â^'WDR5 Interaction. Journal of Medicinal Chemistry, 2010, 53, 5179-5185.	6.4	61
33	Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. ACS Medicinal Chemistry Letters, 2010, 1, 85-89.	2.8	80
34	Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3933-3938.	7.1	641
35	Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Molecular Cancer Therapeutics, 2008, 7, 1533-1542.	4.1	87
36	Quantitative Conformationally Sampled Pharmacophore for Î´ Opioid Ligands:Â Reevaluation of Hydrophobic Moieties Essential for Biological Activity. Journal of Medicinal Chemistry, 2007, 50, 1799-1809.	6.4	36

#	Article	IF	Citations
37	Position of Coordination of the Lithium Ion Determines the Regioselectivity of Demethylations of 3,4-Dimethoxymorphinans with L-Selectride. Organic Letters, 2005, 7, 2531-2534.	4.6	18
38	Conformationally Sampled Pharmacophore for Peptidic Î´ Opioid Ligands. Journal of Medicinal Chemistry, 2005, 48, 7773-7780.	6.4	53
39	Functionalization of the 6,14-Bridge of the Orvinols. 2.1 Preparation of 18- and 19-Hydroxyl-Substituted Thevinols and Their Treatment with Benzyl Bromide. Journal of Organic Chemistry, 2005, 70, 1907-1910.	3.2	9
40	Computer-Aided Drug Design: Structure-Activity Relationships of Delta Opioid Ligands. Drug Design Reviews Online, 2005, 2, 277-291.	0.7	8
41	Rearrangement of 5-Trimethylsilylthebaine on Treatment with L-Selectride:Â An Efficient Synthesis of (+)-Bractazonine. Journal of Organic Chemistry, 2003, 68, 1929-1932.	3.2	10
42	2D Conformationally Sampled Pharmacophore:Â A Ligand-Based Pharmacophore To Differentiate Î´ Opioid Agonists from Antagonists. Journal of the American Chemical Society, 2003, 125, 3101-3107.	13.7	61
43	Basic Principles and Practices of Computer-Aided Drug Design. , 0, , 259-278.		0